Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors
Authors:
- Pv VoulgariPVPv Voulgari
- Te MarkatseliTMTe Markatseli
- A ZiogaAZA Zioga
- Aa DrososADAa Drosos
- 1 January 2009
- journal article
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 38 (5) , 328-331
Abstract
To describe immune-mediated skin lesion (IMSL) development in patients during anti-tumour necrosis factor (TNF) therapy. Two hundred and fifty-two patients with rheumatoid arthritis (RA) and 183 with spondyloarthropathies (SpA) treated with anti-TNF inhibitors were analysed to identify IMSLs. Of the 252 patients with RA (146 treated with infliximab, 72 with adalimumab, and 34 with etanercept), 32 developed IMSLs. Eleven patients developed psoriatic skin lesions, 10 presented with granuloma annulare (GA), five had skin vasculitis, two alopecia areata, two discoid lupus erythematosus, one lichenoid eruption (lichen planus), and one vitiligo. Of the 183 patients with SpA (138 treated with infliximab, 37 with etanercept, and eight with adalimumab), 10 cases with IMSLs were identified. All were treated with infliximab. More specifically, six patients with ankylosing spondylitis (AS) developed psoriatic skin lesions, one developed GA, one lichen planus, and one alopecia areata. In addition, one patient with psoriatic arthritis (PsA) developed skin vasculitis. The occurrence of these IMSLs ranged from 3 to 36 months with a median of 20 months. Of all the patients with IMSL development, two with psoriatic skin lesions, two with GA, and one with vasculitis stopped anti-TNF therapy because of the extent and severity of the skin lesions. Our results on patients treated with TNF antagonists strongly support a link between TNF inhibition and IMSL development. Although these clinical complications are rare, clinicians should be aware of their occurrence and should recognize them.Keywords
This publication has 13 references indexed in Scilit:
- Chemokines in the Pathogenesis of Lichenoid Tissue ReactionsJournal of Investigative Dermatology, 2009
- Prevalence of pigmentary disorders and their impact on quality of life: a prospective cohort studyJournal of Cosmetic Dermatology, 2008
- Granuloma annulare induced by anti-tumour necrosis factor therapyAnnals of the Rheumatic Diseases, 2008
- TNFα blockade in human diseases: An overview of efficacy and safetyClinical Immunology, 2008
- A Ring-Shaped EruptionThe American Journal of Medicine, 2006
- Defining Upstream Elements of Psoriasis Pathogenesis: An Emerging Role For Interferon αJournal of Investigative Dermatology, 2005
- Psoriasis induced by anti–tumor necrosis factor therapy: A paradoxical adverse reactionArthritis & Rheumatism, 2005
- Dermatological conditions during TNF-α-blocking therapy in patients with rheumatoid arthritis: a prospective studyArthritis Research & Therapy, 2005
- Tumor necrosis factor biology in experimental and clinical arthritisCurrent Opinion in Rheumatology, 2003
- Treatment of Refractory Churg-Strauss-Syndrome (CSS) by TNF- BlockadeImmunobiology, 2002